title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease,20240923T110500,https://www.globenewswire.com/news-release/2024/09/23/2951251/0/en/uniQure-Announces-Orphan-Drug-Designation-Granted-to-AMT-191-for-the-Treatment-of-Fabry-Disease.html,TRGNF,0.03916,Somewhat-Bullish,0.15702
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease,20240815T110500,https://www.globenewswire.com/news-release/2024/08/15/2930804/0/en/uniQure-Announces-Dosing-of-First-Patient-in-Phase-I-IIa-Clinical-Trial-of-AMT-191-for-the-Treatment-of-Fabry-Disease.html,TRGNF,0.036255,Somewhat-Bullish,0.158973
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease,20231129T120500,https://www.globenewswire.com/news-release/2023/11/29/2787620/0/en/uniQure-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-AMT-191-Gene-Therapy-for-Fabry-Disease.html,TRGNF,0.097259,Somewhat-Bullish,0.16076
uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy  ( ASGCT )  Annual Meeting,20220502T204500,https://www.globenewswire.com/news-release/2022/05/02/2434019/0/en/uniQure-Announces-Multiple-Presentations-at-Upcoming-American-Society-of-Gene-and-Cell-Therapy-ASGCT-Annual-Meeting.html,TRGNF,0.080458,Neutral,0.001122
uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy  ( ASGCT )  Annual Meeting,20220502T204500,https://www.benzinga.com/pressreleases/22/05/g26948470/uniqure-announces-multiple-presentations-at-upcoming-american-society-of-gene-and-cell-therapy-asg,TRGNF,0.076188,Neutral,0.000377
